Clinical trials: Ocular Hypertension Glaucoma
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma
Spaeth/Richman Contrast Sensitivity Test
The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access.
- Trial name
- SPARCS (NCT01300949)
- Testing
- Spaeth/Richman Contrast Sensitivity Test, Pelli-Robson Contrast Sensitivity Chart
- Where
- United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Glaucoma
Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data
To analyze Cosopt® in terms of its effects on ocular perfusion pressure and comprehensive ocular blood flow and in relation to visual field progression and optic nerve structural changes in an ongoing 3 year prospective study…
- Trial name
- NCT01145898
- Testing
- (Cosopt®, prostaglandin)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Indiana University
Glaucoma, Ocular Hypertension
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between…
- Trial name
- NCT00383019
- Testing
- Xalatan, Xalacom
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma, Cataract
Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent
The purpose of this study is to assess long-term (10 years post-CyPass implantation) status of the corneal endothelium in subjects who were implanted with the CyPass Micro-Stent in the COMPASS trial.
- Trial name
- COMPASS XXT (NCT04629521)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 12 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Glaucoma
Interactive Study to Increase Glaucoma Adherence to Treatment
Study participants who receive the I-SIGHT intervention will have higher rates of glaucoma treatment compliance (e.g., medication-taking and refill compliance, return for clinical follow-up) and more positive eye health outcomes…
- Trial name
- I-SIGHT (NCT00794170)
- Testing
- Telephone and Print based intervention
- Where
- 2 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Emory University
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients with open-angle glaucoma or ocular…
- Conditions
- Glaucoma, Ocular Hypertension, Open-angle Glaucoma
- Trial name
- NCT01415401
- Testing
- Brinzolamide 1% / timolol 0.5% maleate fixed combination
- Volunteers
- 57 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
- Trial name
- JUPITER (NCT01895972)
- Testing
- Latanoprostene bunod
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Cataract
A Comparison of Three Different Formulations of Prednisolone Acetate 1%
Generic prednisolone acetate 1% is less effective than Pred Forte 1% or Econopred Plus 1%.
- Trial name
- NCT00345046
- Testing
- Pred Forte, EconoPred Plus, Prednisolone Acetate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Open Angle Glaucoma
MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
The study will evaluate the efficacy and safety of the implant and intra-ocular pressure (IOP) lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery.
- Trial name
- STAR-I (NCT03193736)
- Testing
- MINIject implant
- Where
- 2 sites in India, Panama
- Volunteers
- 26 people
- Sponsor
- iSTAR Medical
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Glaucoma, Ocular Hypertension
Long-Term Non-Interventional Latanoprost Study
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin…
- Trial name
- LYNX (NCT01265719)
- Testing
- No intervention other than routine medical care
- Where
- 29 sites in Belgium, Colombia and 12 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- Mont Blanc (NCT04445519)
- Testing
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial)
- Where
- United States
- Volunteers
- 691 people
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma
Home Tonometry With the I-care Tonometer for Glaucoma
The overall objective of the study is to scope the self-management for self-monitoring glaucoma using home tonometry.
- Trial name
- NCT02656836
- Testing
- Home tonometry, diagnostic study
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Queen's University, Belfast
Glaucoma
Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®
Therapeutic indication: Ocular hypotensive Use: Primary open-angle glaucoma and ocular hypertension. Objectives: To evaluate the safety and tolerability of the preservative-free formulation PRO-122 manufactured by Sophia…
- Trial name
- PRO-122/I (NCT03966365)
- Testing
- PRO-122, Krytantek Ofteno®
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Angle-Closure
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for…
- Trial name
- NCT01151904
- Testing
- brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, latanoprost
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Allergan
Glaucoma, Glaucoma, Open Angle
AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
- Trial name
- NCT02036541
- Testing
- AqueSys XEN 45 Glaucoma Implant
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- AqueSys, Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Variability in Perimetry Study
Improved Assessment of Visual Field Change is a trial aimed at investigating mechanisms of visual field testing variability. The investigators have found using larger stimulus size substantially lowers short-term variability.
- Trial name
- VIPII (NCT01051739)
- Testing
- Comparison of four visual field testing strategies
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development